domingo, 15 de noviembre de 2026
BuscarExplore
es.via.news
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· February 6, 2026

Amazon Q4 Earnings Miss Estimates, Shares Slide on $200B Capex Plan

View original at finance.yahoo.com
“Net sales of $213.4 billion rose 14% year over year, which was ahead of management's guidance of $206-$213 billion”
Verbatim excerpt from the source · short snapshot: read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Graviton5 is up to 40% more price-performant than leading x86 processors

    80% confidence

  • Amazon LEO commercial rollout is expected later in 2026

    80% confidence

  • Net sales guidance for Q1 2026 is between $173.5 billion and $178.5 billion, representing 11% to 15% growth

    80% confidence

  • Graviton is used by more than 90% of the top 1,000 AWS customers

    80% confidence

  • Operating income guidance for Q1 2026 is expected to range between $16.5 billion and $21.5 billion

    80% confidence

  • Shoppers using Rufus show 60% higher purchase completion rates

    80% confidence

  • Plans more than 20 Amazon LEO satellite launches in 2026 and over 30 in 2027

    80% confidence

  • AWS custom chips business including Trainium and Graviton now has a combined annual revenue run rate of more than $10 billion and is growing at triple-digit percentages year over year

    80% confidence

  • Amazon Bedrock is now a multibillion-dollar annualized run rate business with customer spend growing 60% quarter over quarter

    80% confidence

  • Trainium4 is expected to start delivering in 2027

    80% confidence

  • Plans to invest approximately $200 billion in capital expenditures in 2026, predominantly in AWS

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
Un editor revisa los conflictos entre fuentes antes de publicarlos aquí.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,915
hechos rastreados a su fuente, y señalamos los que no se sostienen.
100 entidades seguidas4,915 hechos verificados con la fuente5,585 documentos fuente archivados
Consulta estos datos → isubstrate.com

Datos de trabajo, no la noticia final. Esto es lo que nuestra IA ha leído y extraído de los documentos de origen hasta ahora. Cómo trabajamos las fuentes

Amazon Q4 Earnings Miss Estimates, Shares Slide on $200B Capex Plan: Source | Via News | es.via.news